Achieve life sciences to present new data at the 2025 ats international conference demonstrating that cytisinicline reduced cravings and nicotine intake

Seattle and vancouver, british columbia, may 20, 2025 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its phase 3 orca-3 study will be presented during an oral presentation at the 2025 american thoracic society (ats) international conference in san francisco, ca. presentation details: title: cytisinicline reduces cravings and nicotine intake in people who smoke and don't quit completely session: c95 – public health and policy relevant research format: mini symposium oral presentation date & time: tuesday, may 20, 2025; 2:15 pm – 4:15 pm edt location: 2025 ats international conference the oral presentation will highlight the unique benefit of cytisinicline treatment in clinical trials in reducing nicotine cravings which led to reduced nicotine intake, even in individuals who did not achieve complete smoking cessation.
ACHV Ratings Summary
ACHV Quant Ranking